JP6391574B2 - 種間標的内交差反応性を有する抗体分子を産生する方法 - Google Patents

種間標的内交差反応性を有する抗体分子を産生する方法 Download PDF

Info

Publication number
JP6391574B2
JP6391574B2 JP2015529031A JP2015529031A JP6391574B2 JP 6391574 B2 JP6391574 B2 JP 6391574B2 JP 2015529031 A JP2015529031 A JP 2015529031A JP 2015529031 A JP2015529031 A JP 2015529031A JP 6391574 B2 JP6391574 B2 JP 6391574B2
Authority
JP
Japan
Prior art keywords
species
human
library
reactivity
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015529031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530087A5 (https=
JP2015530087A (ja
Inventor
ジョセプフ ウイルヘルムス デ ハアルド ジョハンネス
ジョセプフ ウイルヘルムス デ ハアルド ジョハンネス
フレデリク ジェロメ ブランチェトト クリストプヘ
フレデリク ジェロメ ブランチェトト クリストプヘ
ポール バン デル ウォニング セバスティアン
ポール バン デル ウォニング セバスティアン
Original Assignee
アルゲン−エックス ビーブイビーエー
アルゲン−エックス ビーブイビーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゲン−エックス ビーブイビーエー, アルゲン−エックス ビーブイビーエー filed Critical アルゲン−エックス ビーブイビーエー
Publication of JP2015530087A publication Critical patent/JP2015530087A/ja
Publication of JP2015530087A5 publication Critical patent/JP2015530087A5/ja
Application granted granted Critical
Publication of JP6391574B2 publication Critical patent/JP6391574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015529031A 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法 Active JP6391574B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (3)

Publication Number Publication Date
JP2015530087A JP2015530087A (ja) 2015-10-15
JP2015530087A5 JP2015530087A5 (https=) 2017-09-21
JP6391574B2 true JP6391574B2 (ja) 2018-09-26

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529031A Active JP6391574B2 (ja) 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法

Country Status (10)

Country Link
US (1) US20150203840A1 (https=)
EP (2) EP2890711B1 (https=)
JP (1) JP6391574B2 (https=)
CN (1) CN104583238A (https=)
AU (2) AU2013310924B2 (https=)
CA (1) CA2878712A1 (https=)
DK (1) DK2890711T3 (https=)
IL (1) IL236523B (https=)
IN (1) IN2015DN00140A (https=)
WO (1) WO2014033252A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375931T3 (es) * 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
EP1606316A2 (en) * 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
DK1899378T3 (da) * 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
JP6033229B2 (ja) * 2010-11-24 2016-11-30 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体

Also Published As

Publication number Publication date
AU2017204188A1 (en) 2017-07-13
US20150203840A1 (en) 2015-07-23
EP2890711B1 (en) 2017-01-04
IL236523A0 (en) 2015-02-26
EP2977386A1 (en) 2016-01-27
IL236523B (en) 2018-12-31
DK2890711T3 (en) 2017-02-27
CA2878712A1 (en) 2014-03-06
AU2013310924B2 (en) 2017-08-03
CN104583238A (zh) 2015-04-29
EP2890711A1 (en) 2015-07-08
WO2014033252A1 (en) 2014-03-06
AU2013310924A1 (en) 2015-01-29
IN2015DN00140A (https=) 2015-06-12
AU2013310924A8 (en) 2015-04-30
JP2015530087A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
JP6391574B2 (ja) 種間標的内交差反応性を有する抗体分子を産生する方法
US12442106B2 (en) Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
US11629434B2 (en) Antibody screening methods
JP2022513694A (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
JP2017538656A (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
JP6338235B2 (ja) 低分子化抗体のスクリーニング方法及び製造方法
CN119698434A (zh) 抗gprc5d纳米抗体及其应用
CN117043187A (zh) GARP/TGFβ1抗体及其应用
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
CN114163528B (zh) Cd47结合分子及其应用
CN114746443A (zh) 抗gdf15抗体
Wang et al. Construction and characterization of phage display library: recognition of mouse serologically detected male (SDM) antigen
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
CN120137037A (zh) Cd3的特异性结合蛋白及其制备方法和应用
Rodríguez et al. Generation and NGS profiling of naïve rabbit antibody libraries for efficient monoclonal antibody selection
KR20240150779A (ko) 고양이과 항체 라이브러리
CN121219319A (zh) 抗tigit抗体及其应用
HK40063514A (en) Engineered cd25 polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170803

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170809

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180821

R150 Certificate of patent or registration of utility model

Ref document number: 6391574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250